Compare Crispr Therapeutics AG (CRSP) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KLA Corp. — how do they compare? Crispr Therapeutics AG trades at $54.4 (market cap $5.23B), while KLA Corp. trades at $207.46 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 50.1× Crispr Therapeutics AG's market cap, and KLA Corp. pays a 0.46% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | KLAC | |
|---|---|---|
Market Cap | $5.23B | $261.92B |
Sector | Health | Technology |
52-Week High | $76.78 | $301.71 |
52-Week Low | $44.34 | $84.39 |
Enterprise Value | $3.65B | $263.17B |
Dividend Yield | — | 0.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
KLA Corporation (KLAC) trades at $192.74, down 2.71% on the day, amid a broader semiconductor sector pullback. The stock shows strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation ratios remain elevated with a P/E of 54.77. Recent corporate actions include a 1:10 stock split and dividend declarations, while technical indicators signal near-term bearish pressure with key support at $189.
KLAC presents a compelling long-term investment case driven by AI-driven semiconductor equipment demand and consistent earnings beats, but faces risks from high valuation and sector volatility. Analyst consensus remains bullish with a $246.93 price target implying 28% upside, though investors should monitor execution against growth expectations and competitive dynamics in the semiconductor equipment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
